We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Diatron MI Plc

Develops, manufactures and markets hematology analyzers, clinical chemistry analyzers, and associated reagents for hu... read more Featured Products: More products

Download Mobile App





Diatron Exhibits Abacus 5 and Aquila Hematology Analyzers

By LabMedica International staff writers
Posted on 08 Feb 2017
Print article
Image: The Aquila hematology analyzer (Photo courtesy of Diatron).
Image: The Aquila hematology analyzer (Photo courtesy of Diatron).
Diatron, which develops, manufactures and markets hematology analyzers, and clinical chemistry analyzers, showcased its latest products, the Abacus 5 and Aquila hematology analyzers, at MEDLAB 2017, the world’s largest laboratory exhibition and congress in the Middle East.

One of the world’s top hematology analyzer manufacturers, the Hungarian company’s product range also includes hematology reagents, hematology control material, clinical chemistry analyzers, clinical chemistry reagents, and clinical chemistry controls.

At MEDLAB 2017, held at the Dubai International Convention & Exhibition Centre, UAE, from February 6-9, 2017, Diatron showcased the most advanced model in its range of hematology analyzers, the Abacus 5, which utilizes patented laser-based optical measurement technology developed by the company. The Abacus 5 provides a complete 26 parameter report, including optical determinations of the 5-part WBC differential count. It offers open and closed tube sampling options and has a throughput of 60 samples per hour in either stat or autoloader mode. The Abacus 5 hematology analyzer is one of the smallest 5-part differential analyzers available in the market and requires minimal bench space, thus making it ideal for use in space-restricted environments such as clinics and small to medium laboratories.

Diatron also exhibited Aquila, a 3-part differential hematology analyzer that can be used in any testing location and application where high quality CBC results are desired. The Diatron Aquila provides 3-part differential hematology results using less than 20 μl of whole blood and can operate in a closed or open tube mode. The system has a throughput of up to 60 tests per hour, and its compact size and unique on board reagent pack means that it requires little work and storage space. The Diatron Aquila can easily be moved from testing site to testing site and has an optional battery pack to support mobile testing needs and/or un-reliable main power supply locations.

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.